Healthcare · Drug Manufacturers - Specialty & Generic
Made onJul 22, 2026
Price at call$75.33
6-month call Bull +14.8%
Target by Jan 2027$86.50
Great value below$68.00
Modelv0.6.0
Projection vs Actual
(6M history + forecast)
The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change+14.8% to $86.50
Predicted High$86.50at 6 months
Predicted Low$74.20in 2 weeks
Max Drawdown (predicted)-1.5%
Forecast
The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded.
Predicted Jul 22, 2026 6:51 am
Bull
ZTS trends higher to
$86.50
(+14.8% from $75.33)
by Jan 2027.
dip-then-recover
ThesisZTS is deeply oversold on a broken-compounder narrative but retains best-in-class quality; near-term earnings on Aug 6 is the key catalyst that can either extend the pain or begin a slow mean-reversion toward fair value. Expect choppy action into the print, then a gradual grind higher as value gravity reasserts over months, ending below full fair value as sentiment scars linger.
Invalidated ifAnother guide-down at Aug 6 print or break below $68 bear anchor invalidates the recovery path; sustained close under $70 kills the thesis.
Checkpointtime after the call
Datewhen it gets graded
Predictedthe claim: closing price
Current priceactual close — fills in over time
Predicted returnpredicted vs $75.33 at call
Conv.brain's confidence, 1–10
Driverwhy the brain put the point here
Prediction made
Jul 22, 2026
—
$75.33at call
—
—
The anchor — every point below is measured from this price and date.
2 weeks
Aug 5, 2026
$66.67–$83.99typical range · internal point $74.20
—
±11.5%
6/10
Drift lower into earnings on cautious positioning
What actually happened:
closed $76.04
on Aug 4, 2026 = +0.9% vs the call
(predicted -1.5%)
· direction HIT
(called flat, was flat)
· off by 2.4 pp
· accuracy 9/10
· typical range ±11.5%:
inside the band
· S&P +3.2%
over the same window — lagged it
1 month
Aug 22, 2026
$62.78–$87.88typical range · internal point $77.50
—
±16.7%
4/10
Post-earnings reaction; beat streak vs guide risk
What actually happened:
closed $77.74
on Aug 21, 2026 = +3.2% vs the call
(predicted +2.9%)
· direction HIT
(called flat, was flat)
· off by 0.3 pp
· accuracy 10/10
· typical range ±16.7%:
inside the band
· S&P +2.3%
over the same window — beat it
2 months
Sep 22, 2026
$79.80
—
+5.9%
5/10
Stabilization as oversold condition unwinds
3 months
Oct 22, 2026
$82.00
—
+8.9%
5/10
Value buyers step in below fair value anchors
4 months
Nov 22, 2026
$83.50
—
+10.8%
5/10
Next print and quality reassertion aid drift
5 months
Dec 22, 2026
$85.00
—
+12.8%
4/10
Year-end rotation into quality defensives
6 months
Jan 22, 2027
$86.50
—
+14.8%
4/10
Gradual convergence toward composite fair value
Why ranges on the short rungs?
A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here —
three prompt formulations all lost to simply predicting zero — while the stock's own
volatility scale (σ×√t) described those windows well. So the short rungs claim what's
actually knowable: the typical travel, with earnings timing flagged where the variance
will come from. The internal point calls keep being generated and graded to map where
real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.
Deterministic control (v0.3 value line) targets
$84.29
(+11.9%)
— both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it.
Brain: claude-opus-4-7.
Weaknesses
No weaknesses recorded for this run.
All inputs present, no fallbacks used — nothing to flag.
Equation Inputs
Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.
Value anchors (from deep analysis)
Price at call
$75.33
Composite fair value
$90.31
Signal-adjusted fair value
$89.15
DCF fair value
$81.54
Anchored-PE fair value
$123.20
Buy-below (value lens)
$68.00
Value net score
+32
Value confidence
6 / 10
Quality net score
+85
Memo confidence
7 / 10
Deserved value (base)
—
Quality tilt
—
Deserved value (used)
—
Coherence (value × quality)
—
Price behaviour (trailing — shapes the realism line)
Realized volatility (annualized)
1m 29.1% 3m 57.7% 6m 45.2%
Daily σ (realism noise)
3.6%
Beta vs S&P 500
1m -0.88 3m 0.21 5m 0.63
Trailing 6-month return
-39.4%
Knobs (equation params)
ladder
Array
llm_model
claude-opus-4-7
max_tokens
3000
control_knobs
Array
Neutral band (%)
5
earnings_brief
v1
prompt_version
p1
control_version
v0.3.0
Version & Tech Chain
What produced this prediction — stamped on the record so versions can be compared by success rate later.
Modelv0.6.0#271041f8fcd5
Tech composition (what this version is built from)
#
Process
Kind
Group
1
Synthesisvaluation-synthesis
deterministic
final
2
Scenario Analysisscenario-valuation
deterministic
valuation
3
Valuation / Mispricingext-lens-value
llm
extended
4
Company Qualityext-lens-quality
llm
extended
5
Forensic Memo (combiner)ext-forensic-memo
llm
extended
6
Classificationcompany-classification
llm
foundation
7
Live Quotefmp-quote
data
market-data
Inputs used (the runs that fed this prediction)
Upstream process
Ran
Lag
Run id
company-classification
Jun 3, 2026
47d behind
ZTS-20260603-190341-36a7
ext-forensic-memo
Jul 21, 2026
freshest
ext-ZTS-20260721-110055-ad9a
ext-lens-quality
Jul 21, 2026
freshest
ext-ZTS-20260721-110055-ad9a
ext-lens-sentiment
Jul 21, 2026
freshest
ext-ZTS-20260721-110055-ad9a
ext-lens-value
Jul 21, 2026
freshest
ext-ZTS-20260721-110055-ad9a
scenario-valuation
Jul 21, 2026
freshest
ZTS-20260721-105554-83a3
valuation-synthesis
Jul 21, 2026
freshest
ZTS-20260721-105554-83a3
Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.
Saved History
2 frozen snapshots — the record we score once predictions mature.